Drug intelligence / Profile preview

AFX-5931

Development stage: Phase 4
Lead developer: Afecta Pharmaceuticals
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

AFX-5931 is an investigational small molecule drug developed by Afecta Pharmaceuticals and LEO Pharma. It acts as an inhibitor of the chemokines CCL2 (C-C motif chemokine 2) and CCL5 (C-C motif chemokine 5), which are key mediators in inflammatory pathways. By targeting these cytokines, AFX-5931 aims to reduce inflammation associated with diseases such as chronic hand eczema and diabetic retinopathy. The drug has been studied primarily for topical use in skin disorders and ophthalmic use for eye disorders. Clinical development included a phase II trial for eczema (now discontinued) and preclinical studies for diabetic retinopathy[1][3][4].

Targets

CCL2 (C-C motif chemokine 2)CCL5 (C-C Motif Chemokine Ligand 5)

Beyond the preview

Go deeper on AFX-5931.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-5931.

Explore the full profile